Regeneron Pharma stock (US75886F1075): focus on Dupixent growth and new eye drug catalysts

Regeneron Pharma remains in the spotlight after its latest quarterly results and ongoing Dupixent expansion. What drives the biotech’s revenue mix, and which catalysts could matter next for US investors?

Regeneron Pharma is again drawing attention from biotech-focused investors after its latest quarterly update highlighted continued growth for key drug Dupixent and a shifting revenue mix between its eye and immunology franchises, according to a results release published on 05/02/2024 by the company’s investor relations site (Regeneron investor relations as of 05/02/2024).

As of: 25.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Regeneron
• Sector/industry: Biotechnology / pharmaceuticals
• Headquarters/country: Tarrytown, United States
• Core markets: US and international prescription drug markets in immunology and ophthalmology
• Key revenue drivers: Dupixent, Eylea/Eylea HD and other antibody-based therapies
• Home exchange/listing venue: Nasdaq (ticker: REGN)
• Trading currency: USD

Regeneron Pharma: core business model

Regeneron Pharma develops, manufactures and commercializes biologic medicines, with a focus on monoclonal antibodies and other targeted therapies that address high unmet medical needs in areas such as eye disease, inflammatory conditions and oncology, according to the company’s corporate profile (Regeneron corporate site as of 04/15/2025).

The company’s model combines in-house research platforms, including its antibody discovery technologies, with commercialization either independently or together with large pharmaceutical partners such as Sanofi, which co-commercializes Dupixent in multiple indications and geographies, according to a collaboration description published on 02/08/2024 (Sanofi press release as of 02/08/2024).

Revenue is generated primarily from product sales, collaboration revenues and, to a lesser extent, other revenue streams such as royalties from partners commercializing drugs discovered with Regeneron technology, according to the company’s 2023 annual report released on 02/02/2024, which describes its business segments and collaboration structures (Regeneron Form 10-K 2023 as of 02/02/2024).

Regeneron’s strategy centers on advancing a broad pipeline of antibody-based candidates across several therapeutic areas while also defending and extending the life cycle of established drugs like eye therapy Eylea and immunology product Dupixent, according to the same filing (Regeneron Form 10-K 2023 as of 02/02/2024).

Main revenue and product drivers for Regeneron Pharma

One of the most important drivers for Regeneron is Dupixent, which is indicated for conditions including atopic dermatitis, asthma and chronic obstructive pulmonary disease (COPD) in certain regions, with the drug recording net product sales of around 10.9 billion USD for the year 2023 under the Sanofi-led sales framework, representing a strong increase versus the prior year, according to a Sanofi earnings release dated 02/08/2024 (Sanofi press release as of 02/08/2024).

Regeneron records its share of Dupixent-related profits and collaboration revenue in its own financial statements, and management highlighted the drug’s contribution to overall top-line growth in the first quarter of 2024, when total revenues reached approximately 3.15 billion USD for the quarter ended 03/31/2024, up from about 3.16 billion USD in the same period a year earlier, according to the company’s Q1 2024 results release on 05/02/2024 (Regeneron investor relations as of 05/02/2024).

Eylea, a vascular endothelial growth factor (VEGF) inhibitor for retinal diseases such as wet age-related macular degeneration, remains another central revenue pillar, though it is facing competition from newer treatments and biosimilars in the ophthalmology space, according to the same quarterly report that noted Eylea’s performance in the United States and abroad (Regeneron investor relations as of 05/02/2024).

To reinforce its position in the eye disease market, Regeneron has also launched Eylea HD (aflibercept 8 mg) in the United States after receiving FDA approval in 2023 for certain retinal diseases, giving physicians a higher-dose formulation that may support longer dosing intervals, according to an approval announcement published on 08/18/2023 (US FDA statement as of 08/18/2023).

Beyond these flagship drugs, Regeneron has built a diversified portfolio that includes products and pipeline assets in oncology, rare diseases and cardiovascular conditions, with Libtayo in oncology and other antibody-based therapies contributing to collaboration and direct sales, as described in its 2023 annual report published on 02/02/2024 (Regeneron Form 10-K 2023 as of 02/02/2024).

Conclusion

Regeneron Pharma offers US investors exposure to a large-cap biotechnology group with leading antibody platforms, a strong commercial franchise around Dupixent and significant presence in the retinal disease market through Eylea and Eylea HD, according to its 2023 annual report and recent quarterly update (Regeneron Form 10-K 2023 as of 02/02/2024).

The company’s pipeline in immunology, oncology and other specialties provides additional optionality, but the revenue base remains concentrated in a few major drugs that face competitive and regulatory pressures over time, as highlighted across its regulatory filings and risk disclosures published in early 2024 (Regeneron Form 10-K 2023 as of 02/02/2024).

For market participants, the stock’s risk-reward profile is shaped by Dupixent growth, the durability of the Eylea franchise, the success of newer launches and pipeline readouts, and overall sentiment towards the biotech sector on Nasdaq.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.